Industry Findings: Expanding public health and diagnostics access mandates — especially in lower-income member countries — are creating a rising collective demand for affordable, scalable diagnostic and monitoring solutions. The World Health Organization’s 2023 global resolution on diagnostics access (WHA76.5) has galvanized multiple BRICS governments to expand lab networks and decentralized diagnostic capacity (May-2023). This macro-level push is reshaping purchasing patterns: from high-end niche instruments to robust, cost-efficient point-of-care and IVD consumables suited for wide population coverage, pressuring vendors to balance reliability with cost sensitivity.
Industry Progression: In recent years, national regulatory bodies across several BRICS countries have initiated post-market surveillance and harmonization efforts to support large-scale device rollouts. For example, regulatory data published by National Medical Products Administration (NMPA) in China – part of BRICS – highlighted in 2024 a sharp increase in device registrations and renewals (+7.5% vs. 2023), signalling both backlog clearance and new device influx into the bloc’s largest market (2024 summary report). That trend supports supply-chain stabilization across BRICS and opens export-import flows for diagnostics and monitoring devices within the bloc.
Industry Player Insights: The industry innovation pulse in BRICS is driven by Mindray, Siemens Healthineers, Roche Diagnostics, and GE HealthCare etc. Mindray’s strong 2024–2025 revenue growth across APAC and BRICS-linked deployments underscores its cost-competitive positioning. Meanwhile, Siemens and Roche continue leveraging global scale and regulatory experience to supply centralized and regional labs. This vendor mix — combining volume-oriented and premium global suppliers — strengthens BRICS procurement flexibility and supports both high-volume IVD throughput and advanced monitoring infrastructure.